Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments.

abstract：:This review summarizes the safety of sorafenib, an oral multikinase inhibitor, focusing on the randomized, placebo-controlled, Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) in renal cell carcinoma, which formed the basis of the approval of sorafenib. Similar to other targeted agents, ...

journal_title：Expert review of anticancer therapy

authors： Hutson TE

更新日期：2007-09-01 00:00:00

abstract：INTRODUCTION:Hormone receptor positive (HR+) breast cancer represents the most common subtype of breast cancer. Metastatic HR+ breast cancer may develop resistance to standard hormone therapies, arising from genomic alterations in the estrogen receptor and/or upregulation of other signal transduction pathways. Areas co...

journal_title：Expert review of anticancer therapy

authors： Vidula N,Rugo HS

更新日期：2018-01-01 00:00:00

abstract：:Raloxifene is a member of a family of drugs known as selective estrogen receptor modulators (SERMs). Raloxifene is currently approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. SERMs hold the potential to treat and prevent breast cancer, osteoporosis and coronary heart disease...

journal_title：Expert review of anticancer therapy

authors： Pappas SG,Jordan VC

更新日期：2001-10-01 00:00:00

abstract：:Limb-salvage surgery plays a major role in the management of patients with osteosarcoma. As prognosis improves, reconstructive options have come under greater scrutiny with regard to their durability and functionality. The advent of computer navigation-guided reconstruction is discussed in detail, along with methods b...

journal_title：Expert review of anticancer therapy

authors： Mangat KS,Jeys LM,Carter SR

更新日期：2011-02-01 00:00:00

abstract：:The purpose of this article is to outline the current approach to patients affected by metastasis to the long bones and to present a clinical and surgical algorithm available for clinicians and for future research. A modern approach to patients affected by long bone metastasis in fact requires a multidisciplinary cont...

journal_title：Expert review of anticancer therapy

authors： Capanna R,Piccioli A,Di Martino A,Daolio PA,Ippolito V,Maccauro G,Piana R,Ruggieri P,Gasbarrini A,Spinelli MS,Campanacci DA,Italian Orthopaedic Society Bone Metastasis Study Group.

更新日期：2014-10-01 00:00:00

abstract：INTRODUCTION:Endometrial cancer is the most common gynecologic malignancy in the developed world, and its incidence is increasing. Mortality from this cancer has not improved in recent decades and is primarily driven by high-grade carcinomas that are more likely to present at an advanced stage and ultimately are more l...

journal_title：Expert review of anticancer therapy

authors： Connor EV,Rose PG

更新日期：2018-09-01 00:00:00

abstract：:Ductal carcinoma in situ is a premalignant disease of the breast with a rapidly rising incidence. For women with localized ductal carcinoma in situ, randomized trials have shown that radiation therapy following conservative surgery lowers the relative risk of progression to invasive disease by 60%. Therefore, followin...

journal_title：Expert review of anticancer therapy

authors： Smith BD,Smith GL,Buchholz TA

更新日期：2008-03-01 00:00:00

abstract：:Introduction: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and the third largest cause of cancer-relateddeaths worldwide. Potentially curative treatments (surgical resection, radiofrequency or liver transplantation) are only available for few patients, while transarterial chemoembolizat...

journal_title：Expert review of anticancer therapy

authors： Casadei-Gardini A,Orsi G,Caputo F,Ercolani G

更新日期：2020-01-01 00:00:00

abstract：:Ovarian cancer is the leading cause of gynecologic cancer-related death in Europe and the USA. The optimal treatment strategy for this malignancy includes accurate presurgical and surgical staging, optimal debulking surgery, and first-line therapy with platinum-based chemotherapy. Unfortunately, the majority of patien...

journal_title：Expert review of anticancer therapy

authors： Guarneri V,Barbieri E,Dieci MV,Piacentini F,Conte P

更新日期：2011-01-01 00:00:00

abstract：:With the association of concurrent chemotherapy, the widespread implementation of altered fractionation schedules and the use of more conformal radiotherapy techniques, the locoregional management of patients with squamous cell carcinoma of the head and neck region (HNSCC) has greatly improved over the last decades. H...

journal_title：Expert review of anticancer therapy

authors： Lambrecht M,Dirix P,Vandecaveye V,De Keyzer F,Hermans R,Nuyts S

更新日期：2010-09-01 00:00:00

abstract：:The development of consensus classifications for renal epithelial neoplasia in 1996 and 1997 led to the recognition of renal adenoma, renal oncocytoma and metanephric adenoma/adenofibroma as benign tumors and conventional (clear cell) renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and collecting duct carci...

journal_title：Expert review of anticancer therapy

authors： Delahunt B,Velickovic M,Grebe SK

更新日期：2001-12-01 00:00:00

abstract：:The retinoblastoma (RB)-Cyclin (CCN)D1-p16 cell cycle pathway has a crucial role in lung tumorigenesis. Impairment of the RB pathway has been shown to occur in almost all lung tumors. A deregulation at any level of this core RB pathway seems to make cells insensitive to the mitogenic signaling that is required for cel...

journal_title：Expert review of anticancer therapy

authors： Wikman H,Kettunen E

更新日期：2006-04-01 00:00:00

abstract：:Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis. In addition, limited active therapeutic options are available. The cytotoxic drug gemcitabine and the inhibition of the mTOR pathway have demonstrated modest activity in sarcomas as monotherapy. However, prec...

journal_title：Expert review of anticancer therapy

authors： Martin-Liberal J,Tirado OM,García del Muro X

更新日期：2015-03-01 00:00:00

abstract：INTRODUCTION:In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 m...

journal_title：Expert review of anticancer therapy

authors： Amaral T,Nouri N,Garbe C

更新日期：2016-07-01 00:00:00

abstract：:Despite being a common cancer worldwide, management of transitional cell carcinoma of the bladder currently relies primarily on clinical staging and histopathologic parameters. Assaying alterations in molecular pathways can contribute valuable information that can accurately predict outcome and chemotherapeutic respon...

journal_title：Expert review of anticancer therapy

authors： Bartsch G,Mitra AP,Cote RJ

更新日期：2010-12-01 00:00:00

abstract：:Regional lymph node irradiation is usually indicated in patients with positive node breast cancer. However, there are some controversies regarding the clinical benefits of adding regional nodal irradiation to whole-breast or thoracic-wall irradiation after breast surgery especially for patients with 1 to 3 positive ax...

journal_title：Expert review of anticancer therapy

authors： Marta GN,de Moraes FY

更新日期：2015-01-01 00:00:00

abstract：:Introduction: The microbiota is recognized for its impact on both human health and disease. The human microbiota is made up of trillions of cells, including bacteria, viruses, and fungi. The largest population of microbes reside in the gut, prompting research for better understanding of the impact of gastrointestinal ...

journal_title：Expert review of anticancer therapy

authors： Garajová I,Balsano R,Wang H,Leonardi F,Giovannetti E,Deng D,Peters GJ

更新日期：2020-12-08 00:00:00

abstract：:Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase I...

journal_title：Expert review of anticancer therapy

authors： Surmont VF,van Meerbeeck JP

更新日期：2011-10-01 00:00:00

abstract：:Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy ...

journal_title：Expert review of anticancer therapy

authors： Prestwich RJ,Harrington KJ,Pandha HS,Vile RG,Melcher AA,Errington F

更新日期：2008-10-01 00:00:00

abstract：:Bone metastases are common among patients with stage IV genitourinary cancers. Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event. These events are associated with increased medical expenses and decreased quality of life. Current guidelines recomme...

journal_title：Expert review of anticancer therapy

authors： Mulders PF,Abrahamsson PA,Bukowski RM

更新日期：2010-11-01 00:00:00

abstract：:Introduction: Even with the currently recommended chemotherapeutic and immunotherapeutic treatment, the five year survival rate for advanced nonsquamous and squamous NSCLC without oncogenic drivers remains poor. However, several different chemo-immunotherapy combinations are presently being investigated - with favorab...

journal_title：Expert review of anticancer therapy

authors： Rocco D,Della Gravara L,Battiloro C,Gridelli C

更新日期：2019-07-01 00:00:00

abstract：:The failure of conventional chemotherapy to improve survival in a large percentage of patients with advanced solid tumors has prompted the development of alternative anticancer approaches. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) relies on myeloablative conditioning to eradicate the under...

journal_title：Expert review of anticancer therapy

authors： Espinoza-Delgado I,Childs RW

更新日期：2004-10-01 00:00:00

abstract：:Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis. It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths. Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical man...

journal_title：Expert review of anticancer therapy

authors： Haleblian GE,Wilson C,Haddad D,Albala DM

更新日期：2007-09-01 00:00:00

abstract：INTRODUCTION:Outcomes in metastatic colorectal cancer are improving, with better understanding and use of targeted therapies. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This article reviews the current ...

journal_title：Expert review of anticancer therapy

authors： Price TJ,Tang M,Gibbs P,Haller DG,Peeters M,Arnold D,Segelov E,Roy A,Tebbutt N,Pavlakis N,Karapetis C,Burge M,Shapiro J

更新日期：2018-10-01 00:00:00

abstract：:The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30 years since the advent of combination chemotherapy with cytarabine arabinoside and daunorubicin with remission rates around 70% but with long term survival still only around 40% in young adults. Doses of chemotherapy have been push...

journal_title：Expert review of anticancer therapy

authors： Kell J

更新日期：2016-01-01 00:00:00

abstract：:Nonmelanoma skin cancer is the most prevalent malignant disease among light-skinned individuals in the USA, accounting for approximately 1 million new cases annually. Solar ultraviolet radiation is known to be the major cause of skin cancer. The idea that diet, particularly dietary fat, may play a role in modulating c...

journal_title：Expert review of anticancer therapy

authors： Black HS

更新日期：2005-10-01 00:00:00

abstract：:Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleo...

journal_title：Expert review of anticancer therapy

authors： Robak T

更新日期：2008-07-01 00:00:00

abstract：:For over 40 years, fluorouracil has been the only drug registered for the treatment of metastatic colorectal cancer. During the past 5 years, combination chemotherapy regimens including either irinotecan or oxaliplatin have proven to be superior to fluorouracil monotherapy in randomized clinical trials, in terms of re...

journal_title：Expert review of anticancer therapy

authors： Pessino A,Sobrero A

更新日期：2006-05-01 00:00:00

abstract：:Lung cancer develops in a stepwise fashion, with an accumulation of molecular alterations progressing through preinvasive steps to invasive disease. This progression could be arrested or reversed through pharmacologic treatments, which are known as cancer chemoprevention. Preclinical and clinical findings relating to ...

journal_title：Expert review of anticancer therapy

authors： Cohen V,Khuri FR

更新日期：2005-06-01 00:00:00

abstract：:For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). After the demonstration of rituximab's single-agent activity in DLBCL, a pi...

journal_title：Expert review of anticancer therapy

authors： Murawski N,Zwick C,Pfreundschuh M

更新日期：2010-03-01 00:00:00